CYP19A1 and breast cancer: Currently, drugs that block the aromatisation of androgens to oestrogen via inhibition of a key synthesising enzyme namely cytochrome P450 (CYP450) aromatase (human aromatase; HA) are considered the first-line choice for the management of ER + BC (e.g. letrozole and anastrozole; 1 and 2).4